Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DexCom, a provider of continuous glucose monitoring systems, has amended its joint development agreement with Animas to extend outside the US.
Subscribe to our email newsletter
DexCom said that this revised agreement gives Animas exclusive rights to DexCom CGM technology, now and in the future, for integration into Animas insulin pumps outside the US. Animas also retains the non-exclusive right to develop and market CGM-enabled ambulatory insulin pumps within the US.
Under the terms of the agreement, Animas will receive an exclusive right to develop and market CGM-enabled ambulatory insulin delivery systems outside the US. Animas will pay DexCom a one-time $5 million milestone payment upon the first regulatory body approval outside the US for the new system.
In addition, Animas will contribute $300,000 to offset a portion of DexCom’s development expenses for the new system. The parties have also entered into a commercialization agreement under which Animas will obtain distribution rights for DexCom sensors and transmitters to users of the integrated system and will pay a royalty to DexCom for each CGM-enabled pump sold outside the US. The initial term of the development agreement is three years and the initial term of the commercialization agreement is three years from the first commercial product launch.
The initial product will be based on Animas’s advanced pump technology and DexCom’s SEVEN continuous glucose monitoring system. The new technology will enable the Animas pump to receive glucose readings from the DexCom transmitter and display this information on the pump’s color screen. Users will have access to real-time glucose information and trends in addition to receiving alerts for low and high glucose readings.
Having real-time readings displayed on the pump screen may allow users to make more timely adjustments to their insulin delivery, and will also eliminate a separate receiver, reducing the amount of equipment required to use CGM and the pump system, said DexCom.
The Animas insulin pump allows users to increase or decrease their insulin amounts with just a few button presses, based on their blood glucose levels, what they eat, activity and metabolic influences, added DexCom.
According to DexCom, its SEVEN system, the only approved seven-day CGM system, measures glucose throughout the day and night, allowing users to see trends and patterns in glucose readings.
DexCom anticipates that the integrated system will be available to patients in the first half of 2010.